Frontiers in surgery · 2025
Effects of single femoral nerve block and continuous femoral nerve block on perioperative analgesia and muscle strength in elderly patients undergoing total knee arthroplasty, a randomized clinical trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tao Yan, Cai Nan, Zhang Juxia, Zhou Yan, Liu Pengfei
Аннотация
OBJECTIVE: To investigate the effect of single femoral nerve block (SFNB) with 0.2% ropivacaine 50 ml on postoperative pain and muscle strength in elderly patients undergoing knee replacement.
METHODS: Ninety-four patients scheduled for primary total knee arthroplasty (TKA) were randomized into two groups. The patients in the SFNB group received SFNB with 50 ml 0.2% ropivacaine (n = 48), while the patients in the continuous femoral nerve block (CFNB) group (n = 46) received CFNB with an initial load of 20 ml 0.5% ropivacaine and a continuous injection of 0.2% ropivacaine at a rate of 5 ml/h. After the surgery, all patients were administered patient-controlled intravenous analgesia. The primary outcome was the visual analogue scale (VAS) score at 24 h postoperatively. The secondary outcomes included: (a) Pain scores at 2 h, 6 h, 12 h, 48 h, and 72 h after surgery, and the total dosage of celecoxib; (b) Muscle strength of the quadriceps at 2 h, 6 h, 12 h, 24 h, 48 h, and 72 h postoperatively; (c) Range of motion (ROM) at 24 h, 72 h, and 1 week after surgery; (d) American Knee Society knee score (AKS) at 1 week postoperatively; (e) Related complications (e.g., nausea and vomiting), and length of hospitalization; (f) General Comfort Questionnaire (GCQ) score at 72 h postoperatively.
RESULTS: (a) There were no statistically significant differences in VAS scores (p > 0.05) or the total dosage of celecoxib (p > 0.05) between the two groups at various time points; (b) The muscle strength scores in the SFNB group were higher than those in the CFNB group (p < 0.05) at 6 h, 12 h, and 24 h postoperatively; (c) Knee ROM in the SFNB group was better than in the CFNB group (p < 0.05); (d) There were no significant differences in adverse events between the two groups (p > 0.05); (e) The physiological and psychological scores on the GCQ in the SFNB group were higher than those in the CFNB group (p < 0.05).
CONCLUSION: SFNB, with 0.2% ropivacaine 50 ml provides effective pain relief, and improves patient comfort after surgery, without increasing adverse effects. SFNB is a safe and convenient option for postoperative pain management following knee surgery.
METHODS: Ninety-four patients scheduled for primary total knee arthroplasty (TKA) were randomized into two groups. The patients in the SFNB group received SFNB with 50 ml 0.2% ropivacaine (n = 48), while the patients in the continuous femoral nerve block (CFNB) group (n = 46) received CFNB with an initial load of 20 ml 0.5% ropivacaine and a continuous injection of 0.2% ropivacaine at a rate of 5 ml/h. After the surgery, all patients were administered patient-controlled intravenous analgesia. The primary outcome was the visual analogue scale (VAS) score at 24 h postoperatively. The secondary outcomes included: (a) Pain scores at 2 h, 6 h, 12 h, 48 h, and 72 h after surgery, and the total dosage of celecoxib; (b) Muscle strength of the quadriceps at 2 h, 6 h, 12 h, 24 h, 48 h, and 72 h postoperatively; (c) Range of motion (ROM) at 24 h, 72 h, and 1 week after surgery; (d) American Knee Society knee score (AKS) at 1 week postoperatively; (e) Related complications (e.g., nausea and vomiting), and length of hospitalization; (f) General Comfort Questionnaire (GCQ) score at 72 h postoperatively.
RESULTS: (a) There were no statistically significant differences in VAS scores (p > 0.05) or the total dosage of celecoxib (p > 0.05) between the two groups at various time points; (b) The muscle strength scores in the SFNB group were higher than those in the CFNB group (p < 0.05) at 6 h, 12 h, and 24 h postoperatively; (c) Knee ROM in the SFNB group was better than in the CFNB group (p < 0.05); (d) There were no significant differences in adverse events between the two groups (p > 0.05); (e) The physiological and psychological scores on the GCQ in the SFNB group were higher than those in the CFNB group (p < 0.05).
CONCLUSION: SFNB, with 0.2% ropivacaine 50 ml provides effective pain relief, and improves patient comfort after surgery, without increasing adverse effects. SFNB is a safe and convenient option for postoperative pain management following knee surgery.